Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Trametinib Dimethyl Sulfoxide 0.5635mg eqv trametinib
NOVARTIS (SINGAPORE) PTE LTD
L01EE01
TABLET, FILM COATED
Trametinib Dimethyl Sulfoxide 0.5635mg eqv trametinib 0.5mg
ORAL
Prescription Only
GlaxoSmithKline Manufacturing SpA
ACTIVE
2017-02-27
Mekinist Nov 2023.SIN Page 1 of 46 1 TRADENAME MEKINIST ® 0.5 mg and 2 mg film-coated tablets. 2 DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM 0.5 MG FILM-COATED TABLETS Yellow, modified oval, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘TFC’ on the opposing face. Yellow, ovaloid, biconvex, unscored film-coated tablets with beveled edges and with the Novartis logo debossed on one side and ‘TT’ on the other side. 2 MG FILM-COATED TABLETS Pink, round, biconvex, film-coated tablets with ‘GS’ debossed on one face and ‘HMJ’ on the opposing face. Pink, round, biconvex, unscored film-coated tablets with beveled edges and with the Novartis logo debossed on one side and ‘LL’ on the other side. Certain dosage strengths and dosage forms may not be available in all countries. ACTIVE SUBSTANCE 0.5 MG FILM-COATED TABLETS Each film-coated tablet contains trametinib-dimethylsulfoxide (1:1) equivalent to 0.5 mg trametinib. 2 MG FILM-COATED TABLETS Each film-coated tablet contains trametinib-dimethylsulfoxide (1:1) equivalent to 2 mg trametinib. EXCIPIENTS TABLET CORE: mannitol, microcrystalline cellulose, hypromellose, croscarmellose sodium, magnesium stearate (vegetable source), sodium laurylsulfate, colloidal silicon dioxide. TABLET FILM COATING: hypromellose, titanium dioxide, polyethylene glycol, iron oxide yellow (for 0.5 mg tablets), polysorbate 80 and iron oxide red (for 2 mg tablets). Pharmaceutical formulations may vary between countries. 3 INDICATIONS UNRESECTABLE OR METASTATIC MELANOMA Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation ( _see _ _section 6 Warnings and Precautions and section 12 Clinical studies_ ). Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy _(see section 12 Clinical studies)_ . Mekinist Nov 2023.SIN Page 2 of 46 ADJUVANT TREATMENT OF MELANOMA Tramet Read the complete document